🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Jenburkt Pharmaceuticals Limited JENBURPH NSE

Company Profile ↓
₹1,038.80
+1.22% 1Y
Mkt Cap₹458.45 Cr
P/E13.20
P/B2.30
52W High₹1,051.20
52W Low₹1,007.89
Book Value₹446.47
EPS (TTM)₹78.71

Company Overview

Jenburkt Pharmaceuticals Limited (JENBURPH) is a publicly traded company listed on NSE with a market capitalization of ₹458.45 Cr. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 17.6%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 20.0%.

Consistent Profit Growth

Net profit has compounded at 12.2% per year over the last five years.

Reasonable Valuation

Trades at an undemanding P/E of 13.2.

Healthy Margins

Maintains a net profit margin of 20.6%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹168.74 Cr (+11.2% YoY); net profit ₹34.74 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +11.2%, earnings +8.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 7.4%, profit CAGR 12.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:7.42%
1 Year:11.24%

Compounded Profit Growth

5 Years:12.18%
1 Year:8.34%

Stock Price Performance

1 Year:+1.22%
6 Months:-
3 Months:-
1 Month:-

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 71% of range
₹1,007.89 ₹1,051.20
Price Performance
1Y+1.22%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 20.0%.
  • Excellent profit margin of 20.6%.
  • Profit CAGR of 12.2% over 5 years.
  • Generates positive free cash flow.

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
13.20
Industry PE
-
Forward P/E est.
12.18
PEG Ratio
-
Book Value
₹446.47
Price to Book
2.30
P/S
2.69
EV/EBITDA
9.00
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
7.42%
Profit 5Y
12.18%
Revenue (YoY)
11.24%
Earnings (YoY)
8.34%

Profitability & Returns

ROCE
20.03%
ROE
17.63%
ROA
15.37%
Profit Margin
20.59%
Op Margin
24.08%
Gross Margin
80.84%
EPS (Latest Qtr)
₹-
EPS (TTM)
₹78.71

Balance Sheet & Liquidity

Debt/Equity
1.26
Quick Ratio
3.52
Current Ratio
4.11
Debt
₹2.49 Cr
Total Assets
₹226.01 Cr
Current Assets
₹95.09 Cr
Working Capital
₹71.94 Cr

Ownership

Promoter Holding
61.18%
Chg in Prom Hold
-
FII / Inst Holding
0.00%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹458.45 Cr
Total Revenue (TTM)
₹168.74 Cr
EBITDA
₹50.09 Cr
Free Cash Flow
₹12.80 Cr
Operating Cash Flow
₹26.52 Cr
Shares Outstanding
₹44.13 L
Gross Margin
80.84%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Dec 2025Mar 2026
Revenue 36.89 Cr41.05 Cr35.53 Cr43.02 Cr44.63 Cr
Cost of Revenue 7.19 Cr7.90 Cr6.52 Cr8.79 Cr8.66 Cr
Gross Profit 29.71 Cr33.14 Cr29.01 Cr34.24 Cr35.97 Cr
Operating Expenses 21.66 Cr23.08 Cr20.77 Cr27.64 Cr22.53 Cr
Operating Income 8.04 Cr10.07 Cr8.23 Cr6.60 Cr13.44 Cr
EBITDA 10.40 Cr12.74 Cr11.01 Cr9.24 Cr14.65 Cr
Interest Expense 11.03 L11.13 L10.99 L11.55 L12.92 L
Pretax Income 9.51 Cr11.84 Cr10.18 Cr8.30 Cr13.71 Cr
Tax Provision 3.01 Cr3.30 Cr2.39 Cr2.37 Cr2.86 Cr
Net Income 6.51 Cr8.54 Cr7.79 Cr5.93 Cr10.85 Cr
Diluted EPS -----

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -136.14 Cr141.63 Cr151.69 Cr168.74 Cr
Cost of Revenue -33.81 Cr31.14 Cr29.66 Cr32.33 Cr
Gross Profit -102.33 Cr110.50 Cr122.03 Cr136.41 Cr
Operating Expenses -74.22 Cr79.71 Cr84.37 Cr95.78 Cr
Operating Income -28.11 Cr30.78 Cr37.66 Cr40.63 Cr
EBITDA -35.42 Cr37.75 Cr47.11 Cr50.09 Cr
Interest Expense -29.97 L22.99 L45.28 L46.20 L
Pretax Income -32.86 Cr35.18 Cr43.93 Cr46.52 Cr
Tax Provision -8.26 Cr9.20 Cr11.87 Cr11.78 Cr
Net Income -24.61 Cr25.98 Cr32.06 Cr34.74 Cr
Diluted EPS -53.9058.8672.6578.71

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -141.81 Cr165.10 Cr196.19 Cr226.01 Cr
Current Assets -81.09 Cr109.73 Cr56.53 Cr95.09 Cr
Cash & Equivalents -3.66 Cr4.13 Cr7.36 Cr5.58 Cr
Inventory -8.34 Cr8.56 Cr8.88 Cr13.63 Cr
Receivables -16.96 Cr19.48 Cr20.73 Cr24.36 Cr
Total Liabilities -19.42 Cr20.16 Cr24.41 Cr28.97 Cr
Current Liabilities -15.76 Cr16.38 Cr18.82 Cr23.15 Cr
Long Term Debt -----
Total Debt -2.93 Cr03.89 Cr2.49 Cr
Total Equity -122.39 Cr144.94 Cr171.78 Cr197.04 Cr
Shares Outstanding -45.89 L44.13 L44.13 L44.13 L

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -17.05 Cr8.12 Cr27.91 Cr26.52 Cr
Investing Cash Flow -2.62 Cr-58.04 L-17.04 Cr-19.45 Cr
Financing Cash Flow --21.04 Cr-7.08 Cr-7.62 Cr-8.86 Cr
Capital Expenditure --2.10 Cr-2.55 Cr-19.71 Cr-13.72 Cr
Free Cash Flow -14.95 Cr5.57 Cr8.19 Cr12.80 Cr
Net Change in Cash --1.37 Cr46.55 L3.24 Cr-1.79 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -75.2%78.0%80.4%80.8%
Operating Margin % -20.6%21.7%24.8%24.1%
Net Margin % -18.1%18.3%21.1%20.6%
ROE % -20.1%17.9%18.7%17.6%
ROCE % -22.3%20.7%21.2%20.0%

Shareholding Pattern

Insiders
61.18%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for JENBURPH

Google News Wed, 02 Sep 2026

Jenburkt Pharmaceuticals Ltd. (JENBURPH) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE4zYVdIS1JWNFdnZllPakh1SU40V01hSmM0MTdtWnQxUG1sbnVZMEUwbE0tbmZuclR4R1FxNG9ZR2tQM2Q3WTFJYmxYOGp3c1NqeERJaG9zSklLRXho?oc=5" target="_blank">Jenburkt Pharmaceuticals Ltd. (JENBURPH) Pr…

Google News Mon, 17 Aug 2026

Diluted earnings per share (diluted EPS) of Jenburkt Pharmaceuticals Ltd – NSE:JENBURPH - TradingView

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNRXdkWW1EalNFUjNGTGVYSXV1WEZnRUMwWDFIRm5BeHpycG5FUnhGS1pKRzJnb1h6dS13THctanVjOFBXSU9Sdlp0cS1PUW9rZGFiVEVCbjdtUFdmRXVrVDRwc0FDS2lMN0hYd25MWkt3SXlkMkdIV05EU0NhWFp6UWwzXy01UExRUHdPc2…

Google News Wed, 05 Aug 2026

Jenburkt Pharmaceuticals Share Price Rises Over 10% Today - Univest

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxNVmZMV0sxQnlPRFVpbEVLZ2RIcWtxUEJCd3lnUHlFMl8yZzFhQW02SGZMN3dGcGFQbnNrMjNNcTZuODV0dWFTVjNKVGxmYm83N043UHVLVVVxdm1IaWtBQUxNNEdLTjIzRUM2ZmVHTlUwU2taM0RwT3dyRFhYNW5Dc0Y1QlB2ZFpN?oc=5"…

Google News Wed, 19 Aug 2026

Jenburkt Pharmaceuticals Ltd. (JENBURPH) Share Price Today, Quote, Latest Discussions, Interactive Chart and News - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiVEFVX3lxTFBuVU9DdmhTaEE3RzNtZW5CU1JKcFUtVGJpT2JvQi16N1hKU3U4MklVcmo2b2YwY3g0bk9YdkhRb0NDazFNbWUzN0FjNFVUOEp1akNUMQ?oc=5" target="_blank">Jenburkt Pharmaceuticals Ltd. (JENBURPH) Share Price …

Google News Mon, 31 Aug 2026

Jenburkt Pharmaceuticals Ltd. (JENBURPH) News, Articles, Events & Latest Updates - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE50SWl1R3lUZkxVNTFROExxVEsyc2pNWnlLWHYtaV9UTnRfQkQ1ZThPcWVSMG5XYmZKbFgtS0lQMGlwd2YyOVhVS0hBcUk5bUgtMlN2OFhCSld1dHc?oc=5" target="_blank">Jenburkt Pharmaceuticals Ltd. (JENBURPH) New…

Google News Wed, 19 Aug 2026

Jenburkt Pharmaceuticals Ltd. (JENBURPH) Fundamental and Financial Data - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE5EaTlmSmFQWGZISTVjdWRETmNaOEt4U2ZkOWFpMDliblp1Ynp5VDFXb1diRzRETzQ2TkZWOVA2UjJ2UmRQY3RkdzI0eUxQLVJkLVJSWW80WlBxYm91RnQ0ZXYyV01HUQ?oc=5" target="_blank">Jenburkt Pharmaceuticals Ltd.…

JENBURPH — Frequently Asked Questions

What is the current share price of Jenburkt Pharmaceuticals Limited (JENBURPH)?

As of 2026-09-08 04:53 IST, Jenburkt Pharmaceuticals Limited (JENBURPH) trades at ₹1,038.80 on NSE. Its 52-week range is ₹1,007.89 to ₹1,051.20.

What is the market capitalisation of JENBURPH?

Jenburkt Pharmaceuticals Limited (JENBURPH) has a market capitalisation of ₹458.45 Cr on NSE.

What is the P/E ratio of JENBURPH?

JENBURPH trades at a trailing price-to-earnings (P/E) ratio of 13.20. Its price-to-book (P/B) ratio is 2.30.

What is the return on equity (ROE) of JENBURPH?

JENBURPH has a return on equity (ROE) of 17.63%. Its return on capital employed (ROCE) is 20.03%.

Is JENBURPH a good stock to buy?

This page provides a data-driven analysis of Jenburkt Pharmaceuticals Limited (JENBURPH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space